A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA - Wikidata - wikimedia - TriplyDB

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

http://www.wikidata.org/entity/Q24289279

about

Developing Global Norms for Sharing Data and Results during Public Health Emergencies The 2014–2015 Ebola outbreak in West Africa: Hands On Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report Clinical development of Ebola vaccines Filoviruses: One of These Things is (not) Like the Other Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice Vaccine testing for emerging infections: the case for individual randomisation A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis Insights from clinical research completed during the west Africa Ebola virus disease epidemic.The Ebola outbreak, 2013-2016: old lessons for new epidemics.Monoclonal antibodies for the treatment of Ebola virus disease.[Overview of the Ebola vaccines in pre-clinical and clinical development].Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the West African Ebola epidemic 2014-2016: A cross-sectional study.A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, doub Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization.Ebola and the need for restructuring pharmaceutical incentives.Ebola response in Sierra Leone: The impact on children Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.Immunization with Ty21a live oral typhoid vaccine elicits crossreactive multifunctional CD8+ T-cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A, and S. Paratyphi B in humans Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies.Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material.A long-lasting, single-dose nasal vaccine for Ebola: a practical armament for an outbreak with significant global impact Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever.Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid Bioengineering of Tobacco Mosaic Virus to Create a Non-Infectious Positive Control for Ebola Diagnostic Assays Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle.Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines.Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus.Immunology of protection from Ebola virus infection.Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology

P2860

Q23331292-A6181057-CB14-4F2D-9E3D-EA1D63D33687 Q24049114-0D016AB8-90A3-405B-9E14-1BB23B470B2F Q24273364-D726F1D6-EB33-4823-AAE4-CBAE61C867DB Q24289281-00583A1B-F136-424C-B84D-0C2167AA93E5 Q24289295-626BDD4C-F895-4CCC-AB99-C5DC48288F54 Q26775792-726A3F45-0446-45A1-9B85-710DFF71E3F1 Q26783063-57E67480-5995-42E3-960E-000320D19FF9 Q27303766-46321F66-A516-4D7C-9BDC-1C66865D21D1 Q29451722-4618ABBD-242F-416C-8B32-FF7DC1A10CD4 Q29994671-6C5EFEE0-F58D-44E6-A336-4959475E07A3 Q30204075-DC6666FB-6533-4C8E-807B-7F8C8C5D6ADA Q30234590-34324EDF-AA8C-48CF-B693-36B1AF662F4B Q30234874-81A92AD5-E96F-427B-B99B-DB2D681109AE Q30245073-F334AE92-3718-493C-97CC-C2732CB828CD Q30245207-9916BB1B-7174-4456-A150-B07FA109C544 Q33693686-2B12AE04-51D3-4151-9927-0262751B4286 Q33724960-8F4423E4-D754-4079-B67E-A933043678EA Q33798074-6783523A-9862-43B3-961F-90D151DC7622 Q33868760-3D5EE771-BF4E-4CAA-9478-F624E84575D8 Q34500955-9EFFE389-90AC-4E55-95F7-F7163C8F7C0B Q34509612-745E4D9F-0752-4D5A-B86D-A2E04411DA64 Q35109826-70FC7212-5CDB-48F4-AD79-270CA43CAFAC Q36017586-13D63CEA-ABBC-4BCA-A688-4A5C5B7F329A Q36043284-E1470EE2-BF0A-421D-9568-71246B98F269 Q36166784-09820A69-1EBB-435F-807D-F20E8F39E6CB Q36178499-6A025E1B-EEC9-485A-8140-557FF2974322 Q36291682-19B9B6A4-1488-4603-9AD9-A132D661FABB Q36347381-04DAFC08-14EA-46FE-8ED0-6C8286F33D73 Q36394177-A6E8785B-B85F-4DFD-97DD-965AC79FE6D4 Q36403500-A392335F-240F-415A-B769-B183F19442C2 Q36474341-DB43827B-D039-41A2-9CFE-69465BF5770C Q36548980-18E34A29-BD50-40BE-82AB-C76B834E5737 Q36700388-32B0ED5E-2D43-455C-A197-23116870F195 Q36748120-023F3B69-F08F-42D3-B44A-4605DCA903E6 Q36852321-C33584BE-9083-4DE7-BDF4-D2711C3DD694 Q36884852-8EDD0161-5421-4F3E-B609-A334C2AB5EA7 Q37153663-90147A4C-84AB-4D38-BD55-BFE026B3030C Q37581858-7671254F-A70E-451E-A09F-95DF671B807B Q38462668-9E26DDD7-871F-4BB3-9A96-6B5427A3780F Q38675435-471F5CA1-282D-440B-A6B9-37B71B60C9E5

P2860

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

http://www.wikidata.org/entity/Q24289279

description

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

@ast

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

@en

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

@en-gb

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

@nl

type

label

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

@ast

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

@en

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

@en-gb

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

@nl

prefLabel

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

@ast

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

@en

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

@en-gb

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

@nl

P1433

Q24289279-F4AA354E-CD32-4754-AB1B-07E8A8333581

P1476

Q24289279-FF03D4F5-0BD7-4967-A85C-70DF2F5C44CC

P2093

Q24289279-051C6CBE-60AA-47D0-ABF1-0C76C2AA45BB

Q24289279-0C57E61D-46D6-4723-B5D5-558199B6A08B

Q24289279-1605F901-8589-429C-B242-91AB1B026526

Q24289279-1E42A946-3489-4C3E-A65F-89E81BA543E5

Q24289279-1F5B241C-D0F0-4A82-AB9B-DC3CF2542C25

Q24289279-2039A65B-523C-4256-A6CD-3033EC25F72B

Q24289279-214446D7-914C-4144-B396-C676D20CC0CD

Q24289279-3953026B-22C4-4CA6-9CD3-22E671ED206E

Q24289279-40F6C98A-CF37-47F7-B2E3-02A24DEB48C7

Q24289279-42906C3B-7D3D-429A-AA6D-545AE8158C32

P2860

Q24289279-008815D1-6827-4809-8A27-B5BAC1D49436

Q24289279-1B3E820E-8AE8-484A-8971-E33824C77958

Q24289279-2F8E7557-B38D-482D-B3C6-B03C6F5693F2

Q24289279-3590C5C0-E8B7-40D7-A303-8ECC56B47AAA

Q24289279-3990769F-5940-46B9-8C87-99EB448FA1F0

Q24289279-39EC42B4-F2A3-4143-847A-E4AA21E0D2DD

Q24289279-58F205DB-C823-41F5-9603-18E453463D86

Q24289279-5B36FDE5-08D3-4401-BCB2-CAAC32881626

Q24289279-5C9B9B7F-99A3-4115-843F-0819F23A2133

Q24289279-69B73239-E9EA-4ADE-B761-B27AC80BC628

P304

Q24289279-BA84C3EA-8BD5-4DF2-98EE-FCAA15E0AA6B

P31

Q24289279-252C11C4-6C7F-4B17-A9DD-6D98F0C688FF

P3181

Q24289279-D3C50F1C-2085-4093-B277-D0C5447812A3

P356

Q24289279-6F2F11ED-AF66-4CE1-8A1A-040806A2CE1E

P407

Q24289279-F6EEE499-7753-4D41-B36A-1C45065DD6A2

P433

Q24289279-2C6BCD87-E349-4DB8-BECE-C5A5D07529CD

P478

Q24289279-998A249C-89FE-4EB7-A9F4-09709121589D

P50

Q24289279-1D46EC51-75AD-4FF5-8693-8EF06505AC20

Q24289279-2A0C2990-9102-4C55-8186-E3FFB2DC6B9B

Q24289279-3E5CF487-A602-4808-BB73-FACA4FD9E020

Q24289279-44EECBA5-67B5-45DF-87C4-476F6BF26A74

Q24289279-5CDEF893-5241-448C-A796-E6F04E82AFDB

Q24289279-604E26F7-AE64-4E38-AF2F-15CD47A76BA1

Q24289279-6D4590C4-514D-490E-8C77-A5AE251721EC

Q24289279-6F8A801F-310E-43B9-A218-0B890E9E7304

Q24289279-7B1B8509-E4B0-42F3-BEA2-0141EE16F16F

Q24289279-848424CE-347F-4C37-9F63-0076210E49D4

P577

Q24289279-ABB02F07-8013-4FC7-8361-5ADC23FDBBE3

P698

Q24289279-FD03B24A-797B-4CF1-8900-9FDC797BC5CB

P921

Q24289279-0D7C75E2-ED5C-445B-8A54-EEBA6FB2375A

Q24289279-DBE701D3-E511-4F46-8D75-1E5B22199187

Q24289279-F82C42DF-6602-4291-B42F-41AA32AAB672

P932

Q24289279-F8688527-9873-413A-B538-BE4FA51040ED

P3181

P356

P1433

The New England Journal of Medicine

P1476

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

@en

P2093

Adrian V S Hill

http://www.w3.org/2001/XMLSchema#string

Alfredo Nicosia

http://www.w3.org/2001/XMLSchema#string

Alice Minhinnick

http://www.w3.org/2001/XMLSchema#string

Alison Lawrie

http://www.w3.org/2001/XMLSchema#string

Andrew J Pollard

http://www.w3.org/2001/XMLSchema#string

Antonella Folgori

http://www.w3.org/2001/XMLSchema#string

Ariane Volkmann

http://www.w3.org/2001/XMLSchema#string

Carly Bliss

http://www.w3.org/2001/XMLSchema#string

Claire M Tully

http://www.w3.org/2001/XMLSchema#string

Danny Wright

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report

Ebolavirus vaccines for humans and apes

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants.

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.

Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.

P304

1635-1646

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4985597

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1411627

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

374

http://www.w3.org/2001/XMLSchema#string

P50

Myron M. Levine

Sarah Catherine Gilbert

Simon J. Draper

Georgina Bowyer

P577

2015-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25629663

http://www.w3.org/2001/XMLSchema#string

P921

Vaccine against Ebola

P932

5798586

http://www.w3.org/2001/XMLSchema#string